Olysio

J&J discloses DOJ investigations into marketing, advisory practices
BioPharma Dive
Thu, 05/11/17 - 11:43 am
JNJ
DOJ
drug marketing
Remicade
Olysio
Simponi
Stelara
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
Tue, 05/9/17 - 10:43 pm
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
Fri, 09/9/16 - 10:21 am
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
Competition drives down sales of J&J's Olysio
Medical Marketing and Media
Tue, 04/19/16 - 06:13 pm
JNJ
Olysio
earnings
The Worst Johnson & Johnson Headlines in 2015
Motley Fool
Mon, 12/28/15 - 04:32 pm
JNJ
drug pricing
Olysio
Johnson & Johnson Tells Gilead Sciences "Game On"
Motley Fool
Tue, 10/20/15 - 10:08 am
JNJ
Gilead Sciences
hepatitis C
Olysio
Incivek
Harvoni
Sovaldi
J&J Wins U.S. Approval for Hepatitis C Combo With Gilead
Bloomberg
Wed, 11/5/14 - 07:38 pm
JNJ
FDA
Gilead Sciences
hepatitis C
Olysio
If It’s Bad For Merck, It’s Good For Gilead
Barron's
Mon, 10/27/14 - 03:25 pm
Merck
Gilead Sciences
hepatitis C
Sovaldi
JNJ
Olysio
3 Drugs Critical to Johnson & Johnson's Future
Motley Fool
Tue, 10/21/14 - 09:20 am
JNJ
Olysio
Zytiga
Invega Sustenna
Xarelto
Stelara
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Motley Fool
Mon, 10/20/14 - 08:30 am
JNJ
Gilead Sciences
Olysio
hepatitis C
Sovaldi
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Motley Fool
Tue, 07/22/14 - 05:11 pm
JNJ
Olysio
earnings
biosimilars
Do This Drug's Sales Make J&J a Hepatitis C Powerhouse?
Motley Fool
Tue, 07/22/14 - 11:49 am
JNJ
hepatitis C
Olysio
Is This Johnson & Johnson's Worst Nightmare?
Motley Fool
Tue, 07/8/14 - 04:07 pm
JNJ
Zytiga
Medivation
Xtandi
Olysio
Gilead Sciences
Sovaldi
A Primer On The Hepatitis C Market
Yahoo/Investors Business Daily
Fri, 07/4/14 - 11:53 am
hepatitis C
Gilead
Sovaldi
Merck
Victrelis
Incivek
Vertex Pharmaceuticals
Olysio
JNJ
AbbVie
Indenix
Bristol-Myers Squibb
J&J /Gilead HCV Combo Drug Filed
Yahoo/Zacks.com
Thu, 05/8/14 - 05:20 pm
JNJ
Gilead Sciences
hepatitis C
Olysio
Sovaldi
Drugs That Will Help Johnson & Johnson Grow By 5% In 2014
Forbes
Wed, 04/30/14 - 10:28 am
JNJ
Remicade
Olysio
Velcade
Zytiga
J&J-Medivir Hepatitis C Drug Recommended by EU Regulator
Bloomberg
Fri, 03/21/14 - 10:21 am
JNJ
hepatitis C
Europe
Medivir
Olysio
Prices of new hepatitis C drugs are tough to swallow for insurers
LA Times, CA
Mon, 03/10/14 - 08:19 am
insurance
hepatitis C
Sovaldi
Gilead Sciences
Olysio
JNJ
Janssen
What Is Johnson & Johnson's Opportunity In Hepatitis C Market?
Forbes
Wed, 12/11/13 - 09:01 am
JNJ
hepatitis C
Olysio
What Everybody Ought to Know About Gilead and Johnson & Johnson's New Hepatitis C Drugs
Seeking Alpha
Fri, 12/6/13 - 10:30 am
JNJ
Gilead Sciences
hepatitis C
sofosbuvir
Olysio
AbbVie
Bristol-Myers Squibb
Merck

Pages